462 related articles for article (PubMed ID: 33901324)
21. [Clinical Efficacy of Decitabine-Based Chemotherapy Regimens in the Treatment of Newly Diagnosed Elderly Patients with Acute Myeloid Leukemia].
Li GH; Chen RA; Ji YR; Qin WW; Chen Y; Wang WQ; Liu C; Zhou NC; Liu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):743-749. PubMed ID: 29950214
[TBL] [Abstract][Full Text] [Related]
22. [Efficacy and Safety of Decitabine Combined with Modified CAG Regimen in Patients Aged ≥ 70 Years with Newly Diagnosed Acute Myeloid Leukemia].
Cao L; Jiang ZQ; Liu WJ; Sun Q; Zhu Y; Li JY; Qian SX; Hong M
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):633-642. PubMed ID: 37356919
[TBL] [Abstract][Full Text] [Related]
23. Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS.
Mawad R; Becker PS; Hendrie P; Scott B; Wood BL; Dean C; Sandhu V; Deeg HJ; Walter R; Wang L; Myint H; Singer JW; Estey E; Pagel JM
Br J Haematol; 2016 Jan; 172(2):238-45. PubMed ID: 26568032
[TBL] [Abstract][Full Text] [Related]
24. Costs per patient achieving remission with venetoclax-based combinations in newly diagnosed patients with acute myeloid leukemia ineligible for intensive induction chemotherapy.
Choi M; Song J; Bui CN; Ma E; Chai X; Yin L; Betts KA; Kapustyan T; Montez M; LeBlanc TW
J Manag Care Spec Pharm; 2022 Sep; 28(9):980-988. PubMed ID: 35708343
[No Abstract] [Full Text] [Related]
25. [Clinical Efficacy and Survival Analysis of Adult Patients with Acute Myeloid Leukemia after Microtransplantation].
Huang YJ; Zhang JH; Dong CX; Kang JM; Hou YF; Zhang YF; Qi K; Yang LH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1361-1368. PubMed ID: 36208236
[TBL] [Abstract][Full Text] [Related]
26. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.
Zhou X; Mei C; Zhang J; Lu Y; Lan J; Lin S; Zhang Y; Kuang Y; Ren Y; Ma L; Wei J; Ye L; Xu W; Li K; Lu C; Jin J; Tong H
Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434
[TBL] [Abstract][Full Text] [Related]
27. Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study.
Halpern AB; Othus M; Huebner EM; Buckley SA; Pogosova-Agadjanyan EL; Orlowski KF; Scott BL; Becker PS; Hendrie PC; Chen TL; Percival MM; Estey EH; Stirewalt DL; Walter RB
Leukemia; 2017 Dec; 31(12):2560-2567. PubMed ID: 28555084
[TBL] [Abstract][Full Text] [Related]
28. Clofarabine in the treatment of newly diagnosed acute myeloid leukemia in older adults.
Tran H; Yang D
Ann Pharmacother; 2012 Jan; 46(1):89-96. PubMed ID: 22170975
[TBL] [Abstract][Full Text] [Related]
29. Randomized phase 1 study of sequential ("primed") vs. concurrent decitabine in combination with cladribine, cytarabine, G-CSF, and mitoxantrone (CLAG-M) in adults with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) or other high-grade myeloid neoplasm.
Palmieri R; Buckley SA; Othus M; Halpern AB; Percival MM; Scott BL; Hendrie PC; Becker PS; Oehler VG; Estey EH; Walter RB
Leuk Lymphoma; 2020 Jul; 61(7):1728-1731. PubMed ID: 32077361
[No Abstract] [Full Text] [Related]
30. Long-term follow-up of Cladribine, high-dose Cytarabine, and Idarubicin as salvage treatment for relapsed acute myeloid leukemia and literature review.
Mayer K; Hahn-Ast C; Schwab K; Schmidt-Wolf IGH; Brossart P; Glasmacher A; von Lilienfeld-Toal M
Eur J Haematol; 2020 Jun; 104(6):538-545. PubMed ID: 32049382
[TBL] [Abstract][Full Text] [Related]
31. The role of cladribine in acute myeloid leukemia: an old drug up to new tricks.
Molica M; Breccia M; Capria S; Trisolini S; Foa R; Jabbour E; Kadia TM
Leuk Lymphoma; 2020 Mar; 61(3):536-545. PubMed ID: 31752577
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study.
Xu J; Lv TT; Zhou XF; Huang Y; Liu DD; Yuan GL
Medicine (Baltimore); 2018 Sep; 97(39):e12102. PubMed ID: 30278488
[TBL] [Abstract][Full Text] [Related]
33. Low-dose decitabine priming with intermediate-dose cytarabine followed by umbilical cord blood infusion as consolidation therapy for elderly patients with acute myeloid leukemia: a phase II single-arm study.
Li X; Dong Y; Li Y; Ren R; Wu W; Zhu H; Zhang Y; Hu J; Li J
BMC Cancer; 2019 Aug; 19(1):819. PubMed ID: 31429724
[TBL] [Abstract][Full Text] [Related]
34. Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality.
Maiti A; Qiao W; Sasaki K; Ravandi F; Kadia TM; Jabbour EJ; Daver NG; Borthakur G; Garcia-Manero G; Pierce SA; Montalbano KS; Pemmaraju N; Naqvi K; Ohanian M; Short NJ; Alvarado Y; Takahashi K; Yilmaz M; Jain N; Kornblau SM; Andreeff M; Bose P; Ferrajoli A; Issa GC; Masarova L; Thompson PA; Rausch CR; Ning J; Kantarjian HM; DiNardo CD; Konopleva MY
Am J Hematol; 2021 Mar; 96(3):282-291. PubMed ID: 33264443
[TBL] [Abstract][Full Text] [Related]
35. [Efficacy and Safety of Decitabine Combined with Modified EIAG Regimen in the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome].
Mao JP; Xue LG; Zhu YX; Jia T; Wang Y; Miao L; Wei JF; Zhao LD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Apr; 31(2):338-343. PubMed ID: 37096503
[TBL] [Abstract][Full Text] [Related]
36. Minimal residual disease may be an early prognostic indicator for newly diagnosed acute myeloid leukemia patients induced by decitabine-based chemotherapy.
Tan Y; Fu Y; Liu C; Sun J; Liu S; Lin H; Liu Q; Yang Y; Li Y; Su L; Gao S
Hematology; 2019 Dec; 24(1):552-558. PubMed ID: 31315553
[No Abstract] [Full Text] [Related]
37. Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study.
Wei AH; Strickland SA; Hou JZ; Fiedler W; Lin TL; Walter RB; Enjeti A; Tiong IS; Savona M; Lee S; Chyla B; Popovic R; Salem AH; Agarwal S; Xu T; Fakouhi KM; Humerickhouse R; Hong WJ; Hayslip J; Roboz GJ
J Clin Oncol; 2019 May; 37(15):1277-1284. PubMed ID: 30892988
[TBL] [Abstract][Full Text] [Related]
38. Decitabine Versus Intensive Chemotherapy for Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia.
Choi EJ; Lee JH; Park HS; Lee JH; Seol M; Lee YS; Kang YA; Jeon M; Woo JM; Lee KH
Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):290-299.e3. PubMed ID: 30879987
[TBL] [Abstract][Full Text] [Related]
39. Decitabine Compared With Conventional Regimens in Older Patients With Acute Myeloid Leukemia: A Meta-Analysis.
Bian MR; Yang HS; Lin GQ; Wan Y; Wang L; Si YJ; Zhang XX; Wang M; Zhou H; Zhao GS; Zhang YM
Clin Lymphoma Myeloma Leuk; 2019 Dec; 19(12):e636-e648. PubMed ID: 31645307
[TBL] [Abstract][Full Text] [Related]
40. Efficacy outcomes in the treatment of older or medically unfit patients with acute myeloid leukaemia: A systematic review and meta-analysis.
Stone A; Zukerman T; Flaishon L; Yakar RB; Rowe JM
Leuk Res; 2019 Jul; 82():36-42. PubMed ID: 31152922
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
